|
市場調査レポート
商品コード
1439259
経皮ドラッグデリバリーデバイスの世界市場:洞察、競合情勢、市場予測:2030年Transdermal Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。 |
経皮ドラッグデリバリーデバイスの世界市場:洞察、競合情勢、市場予測:2030年 |
出版日: 2024年02月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
|
世界の経皮ドラッグデリバリーデバイスの市場規模は、2024年から2030年までの予測期間中に9.8%のCAGRで拡大すると予測されています。経皮ドラッグデリバリーデバイスの需要は、主に、慢性疾患の有病率の増加、第3世代の経皮ドラッグデリバリーデバイスの採用の増加、デバイスで観察された技術的進歩、ホルモン障害から心血管疾患や疼痛管理へのこれらのデバイスの使用を理由に成長が促進されています。
米国心臓協会(American Heart Association 2022)によると、2020年には全世界で約2億4,410万人が冠動脈性(虚血性)心疾患を患っています。同出典によると、北アフリカ、中東、中央アジア、南アジア、東欧は、2020年に世界で冠動脈性(虚血性)心疾患の有病率が最も高くなっています。
国際アルツハイマー病協会(Alzheimer's Disease International 2020)によると、2020年には世界で5,500万人以上が認知症に罹患しています。その数は20年ごとに倍増し、2030年には8,200万人、2050年には1億5,200万人に達すると予想されています。
片頭痛研究財団によると、2020年には、片頭痛は世界で3番目に多い病気になるといいます。片頭痛は、米国では3,900万人、世界では10億人の男性、女性、子供が罹患している、非常に有病率の高い神経疾患です。したがって、中枢神経系疾患、心血管疾患などの慢性疾患の症例数の増加により、経皮ドラッグデリバリーデバイスの需要が増加し、経皮ドラッグデリバリーデバイスの市場をさらに拡大させると予測されています。
当レポートでは、世界の経皮ドラッグデリバリーデバイス市場について調査し、市場の概要とともに、タイプ別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。
Transdermal Drug Delivery Devices Market By Type (Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Hormonal Applications, Central Nervous System Disorders, Cardiovascular Diseases, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography is expected to grow at a steady CAGR forecast till 2030 owing to the rising prevalence observed in chronic conditions and the increasing demand for third-generation transdermal drug delivery devices.
The global transdermal drug delivery devices market is growing at a CAGR of 9.8% during the forecast period from 2024 to 2030. The demand for transdermal drug delivery devices is primarily witnessing growth on account of the increasing prevalence of chronic conditions, increase in adoption of third-generation transdermal drug delivery devices, technological advancements observed in the device, and the use of these devices from hormonal disorders to cardiovascular conditions and pain management.
Transdermal Drug Delivery Devices Market Dynamics:
According to the American Heart Association 2022, globally, about 244.1 million people were living with coronary (ischemic) heart disease in 2020. As per the same source, North Africa, the Middle East, Central and South Asia, and Eastern Europe had the highest prevalence rates of coronary (ischemic) heart disease in the world in 2020.
According to Alzheimer 's Disease International 2020, worldwide more than 55 million people were suffering from dementia in 2020. The numbers are expected to double every 20 years, reaching 82 million in 2030 and 152 million in 2050.
According to the Migraine Research Foundation, in 2020, migraine accounts to be the third most prevalent illness in the world. It is an extraordinarily prevalent neurological disease, affecting 39 million men, women, and children in the US and 1 billion worldwide. Hence, due to an increase in the number of cases of chronic diseases such as central nervous system disorders, cardiovascular diseases, and others, there will be an increase in demand for transdermal drug delivery devices, fueling the market for transdermal drug delivery devices.
However, certain disadvantages associated with transdermal drug delivery devices such as irritation at the site of application and edema, and certain drugs carrying hydrophilic structures tend to penetrate the skin slowly and do not achieve actual therapeutic levels. These factors are expected to limit the market growth over the forecast period.
Transdermal Drug Delivery Devices Market Segment Analysis:
Transdermal Drug Delivery Devices Market by Type (Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Hormonal Applications, Central Nervous System Disorders, Cardiovascular Diseases, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the application segment of the transdermal drug delivery devices market, pain management can be expected to achieve the largest market share. The reason for this is the rising burden of chronic pain conditions worldwide and the rising availability of transdermal products in the field of pain management.
According to the Centers for Disease Control and Prevention (CDC)/National Center for Health Statistics 2020, about 20.4% of adults had chronic pain in 2019 in the US. As per the same source, 7.4% of adults had chronic pain that frequently limited life or work activities (referred to as high-impact chronic pain) in the past 3 months.
Pain affects the quality of life of a person and interferes with the daily activities of an individual. Transdermal drug delivery devices can help in the effective management of pain.
The rise in the prevalence of chronic pain conditions will demand more transdermal drug delivery devices for the management of pain, thereby fueling the transdermal drug delivery devices market growth.
North America is expected to dominate the Overall Transdermal Drug Delivery Devices Market:
Among all the regions, North America is expected to account for the largest share of the transdermal drug delivery devices market. This can be attributed to the rising prevalence of chronic pain, central nervous system disorders, and cardiovascular disorders in the region, the rising use of contraceptives, and the increase in research-related activities of transdermal drug delivery systems are predicted to be the major influencing factors in driving the overall growth of the market over the forecast period.
The American Heart Association in 2021 projected that by 2035, more than 130 million US adults will have some type of heart disease.
As per the data provided by the Alzheimer Association (2023), more than 6 million Americans are living with Alzheimer's. By 2050, this number is projected to rise to nearly 13 million. The Parkinson's Foundation 2022 data states that every year 90,000 people are diagnosed with Parkinson's in the United States.
The rise in the number of chronic conditions in North America can be thought of to cause a surge in the transdermal drug delivery market within this region.
Transdermal Drug Delivery Devices Market Key Players:
Some of the key market players operating in the transdermal drug delivery devices market include Hisamitsu Pharmaceutical, Mylan, UCB SA, Novartis, GlaxoSmithKline, Boehringer Ingelheim, Johnson & Johnson, Endo International, Purdue Pharma, Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Acrux Limited, Lavipharm, Lead Chemicals Co. Inc., Luye Pharma Group and others.
Recent Developmental Activities in Transdermal Drug Delivery Devices Market:
In July 2020, Hisamitsu Pharmaceutical Co., Inc. announced that it has obtained approval for manufacturing and marketing OABLOK® PATCH in Thailand.
Key Takes Away from the Transdermal Drug Delivery Devices Market Report Study
Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the global transdermal drug delivery devices market.
Various opportunities available for the other competitor in the transdermal drug delivery devices market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for market growth in the coming future?
Target Audience who can be benefited from the Transdermal Drug Delivery Devices Market Report Study
Transdermal Drug Delivery Devices providers
Research organizations and consulting companies
Transdermal Drug Delivery Devices-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders
Various End-Users who want to know more about the transdermal drug delivery devices market and the latest technological developments in the transdermal drug delivery devices market.
Frequently Asked Questions for Transdermal Drug Delivery Devices Market:
Transdermal drug delivery is a procedure that provides drug absorption via the skin. The transdermal drug delivery system is used for the delivery of small, lipophilic, low-dose drugs.
The global transdermal drug delivery devices market is growing at a CAGR of 9.8% during the forecast period from 2024 to 2030.
The major drivers driving the demand for transdermal drug delivery devices are the rising prevalence of chronic conditions, rising adoption of third-generation transdermal drug delivery devices, increase in technological advancements observed in the device, and the use of these devices from hormonal disorders to cardiovascular conditions and pain management.
Some of the key market players operating in the transdermal drug delivery devices market include Hisamitsu Pharmaceutical, Mylan, UCB SA, Novartis, GlaxoSmithKline, Boehringer Ingelheim, Johnson & Johnson, Endo International, Purdue Pharma, Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., and others.
North America is expected to dominate the overall transdermal drug delivery devices market during the forecast period, 2024 to 2030. This domination is due to the rising prevalence of chronic pain, central nervous system disorders, and cardiovascular disorders in the region, the rising use of contraceptives, and the increase in research-related activities of transdermal drug delivery systems in the North American region.